GSK (GSK) stock slips as FDA advisors vote against the approval of a combination regimen involving thecompany's blood cancer drug Blenrep. Read more here.

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing ...

Ten years after the UK became the first country to legalise mitochondrial donation , the first results from the use of these ...

The motor neuron disease treatment market is witnessing substantial growth, primarily fueled by the rising incidence of conditions like Amyotrophic L ...